CA2212552A1 - Hepatitis b vaccine - Google Patents
Hepatitis b vaccineInfo
- Publication number
- CA2212552A1 CA2212552A1 CA002212552A CA2212552A CA2212552A1 CA 2212552 A1 CA2212552 A1 CA 2212552A1 CA 002212552 A CA002212552 A CA 002212552A CA 2212552 A CA2212552 A CA 2212552A CA 2212552 A1 CA2212552 A1 CA 2212552A1
- Authority
- CA
- Canada
- Prior art keywords
- hepatitis
- vaccine
- compromising
- combination
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 title 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 title 1
- 208000002672 hepatitis B Diseases 0.000 abstract 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A novel vaccine formulation is provided, compromising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9503863.4A GB9503863D0 (en) | 1995-02-25 | 1995-02-25 | Vaccine compositions |
| GB9503863.4 | 1995-02-25 | ||
| PCT/EP1996/000681 WO1996026741A1 (en) | 1995-02-25 | 1996-02-15 | Hepatitis b vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2212552A1 true CA2212552A1 (en) | 1996-09-06 |
| CA2212552C CA2212552C (en) | 2006-07-11 |
Family
ID=10770292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002212552A Expired - Fee Related CA2212552C (en) | 1995-02-25 | 1996-02-15 | Hepatitis b vaccine |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US5972346A (en) |
| EP (1) | EP0810877B1 (en) |
| JP (1) | JP3881015B2 (en) |
| KR (1) | KR100365373B1 (en) |
| CN (1) | CN1101225C (en) |
| AP (1) | AP766A (en) |
| AR (1) | AR002279A1 (en) |
| AT (1) | ATE209045T1 (en) |
| AU (1) | AU695921B2 (en) |
| BG (1) | BG101851A (en) |
| BR (1) | BR9607458A (en) |
| CA (1) | CA2212552C (en) |
| CZ (1) | CZ288417B6 (en) |
| DE (1) | DE69617211T2 (en) |
| DK (1) | DK0810877T3 (en) |
| EA (1) | EA199700126A1 (en) |
| ES (1) | ES2166879T3 (en) |
| FI (1) | FI118118B (en) |
| GB (1) | GB9503863D0 (en) |
| HK (1) | HK1004117A1 (en) |
| HU (1) | HU224832B1 (en) |
| IL (1) | IL117249A (en) |
| MA (1) | MA23814A1 (en) |
| MX (1) | MX9706450A (en) |
| MY (1) | MY113428A (en) |
| NO (1) | NO319394B1 (en) |
| NZ (1) | NZ302674A (en) |
| OA (1) | OA10612A (en) |
| PL (1) | PL182679B1 (en) |
| PT (1) | PT810877E (en) |
| SA (1) | SA96160633B1 (en) |
| SK (1) | SK115097A3 (en) |
| TR (1) | TR199700849T1 (en) |
| TW (1) | TW467745B (en) |
| WO (1) | WO1996026741A1 (en) |
| ZA (1) | ZA961460B (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620414B2 (en) * | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
| FR2711670B1 (en) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Nucleotide vector, composition containing it and vaccine for immunization against hepatitis. |
| US6488934B1 (en) * | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
| US20010014331A1 (en) * | 1996-11-07 | 2001-08-16 | Smithkline Beecham Biologicals S.A. | Acellular pertussis vaccine with diphthriae-and tetanus-toxoids |
| US20030049268A1 (en) | 1998-05-01 | 2003-03-13 | Smithkline Beecham Biologicals S.A. | Novel composition |
| GB9809507D0 (en) * | 1998-05-01 | 1998-07-01 | Smithkline Beecham Biolog | Novel composition |
| DE69932717T2 (en) | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY |
| US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| EP1126876B1 (en) | 1998-10-16 | 2007-03-21 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
| CU22871A1 (en) * | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | FORMULATIONS CONTAINING PARTICULARS SIMILAR TO VIRUS AS IMMUNOPOTENCERS BY MUCOSAL ROUTE |
| WO2000037104A1 (en) * | 1998-12-23 | 2000-06-29 | Merck & Co., Inc. | Improved recombinant hepatitis b surface antigen |
| DK1187629T3 (en) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| US6635261B2 (en) | 1999-07-13 | 2003-10-21 | Wyeth Holdings Corporation | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| CU23031A1 (en) * | 2002-01-24 | 2005-02-23 | Ct Ingenieria Genetica Biotech | SURFACE ANTIGEN OF THE HEPATITIS B VIRUS AS A MUCOSOPT IMMUNOPOTENTIATOR, RESULTS FORMULATIONS |
| AP2007004151A0 (en) * | 2005-02-16 | 2007-10-31 | Norvatis Vaccines And Diagnost | Adjuvant composition comprising aluminium phosphate and 3D-MPL |
| WO2007015167A2 (en) * | 2005-08-02 | 2007-02-08 | Novartis Vaccines And Diagnostics Srl | Reducing interference between oil-containing adjuvants and surfactant-containing antigens |
| CA2628328A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| PL2368572T3 (en) | 2005-11-04 | 2020-11-16 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| JP2009514839A (en) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Adjuvant influenza vaccine containing cytokine inducer |
| NZ567978A (en) | 2005-11-04 | 2011-09-30 | Novartis Vaccines & Diagnostic | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| CN100415294C (en) * | 2005-12-23 | 2008-09-03 | 中国农业大学 | Medicine for treating and/or preventing hepatitis B |
| EP3753574A1 (en) | 2006-01-27 | 2020-12-23 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
| EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| WO2007110776A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
| EP1862176A1 (en) * | 2006-05-31 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Method for producing a vaccine composition |
| EP1862177A1 (en) * | 2006-06-01 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Method for producing a vaccine composition |
| US20100015168A1 (en) | 2006-06-09 | 2010-01-21 | Novartis Ag | Immunogenic compositions for streptococcus agalactiae |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| NZ575271A (en) | 2006-09-11 | 2011-09-30 | Novartis Ag | Making influenza virus vaccines without using eggs |
| PL2121011T3 (en) | 2006-12-06 | 2014-10-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| CN101784283A (en) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | Low-additive influenza vaccines |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| WO2009081172A1 (en) | 2007-12-24 | 2009-07-02 | Novartis Ag | Assays for adsorbed influenza vaccines |
| PL3178490T3 (en) | 2009-07-15 | 2022-08-01 | Glaxosmithkline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| EP4144368A1 (en) | 2011-01-26 | 2023-03-08 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
| US9452212B2 (en) | 2011-04-14 | 2016-09-27 | Dynavax Technologies Corporation | Methods and compositions for eliciting an immune response against hepatitis B virus |
| WO2012158613A1 (en) | 2011-05-13 | 2012-11-22 | Novartis Ag | Pre-fusion rsv f antigens |
| EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE159031T1 (en) * | 1989-07-25 | 1997-10-15 | Smithkline Biolog | ANTIGENS AND METHODS FOR THE PRODUCTION THEREOF |
| EP0835639A3 (en) * | 1991-05-29 | 1999-04-07 | Origin Medsystems, Inc. | Retraction apparatus for endoscopic surgery |
| MA22842A1 (en) * | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | PROCESS FOR THE PREPARATION OF VACCINE COMPOSITIONS. |
| CZ283910B6 (en) * | 1992-05-23 | 1998-07-15 | Smithkline Beecham Biologicals (S.A.) | Combined inoculation preparation |
| ES2162139T5 (en) * | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | VACCINE COMPOSITIONS CONTAINING MONOFOSFORIL-LIPIDO TO 3-O-DISABLED. |
| GB9311536D0 (en) * | 1993-06-04 | 1993-07-21 | Unilever Plc | Hot soluble low density extractable food product |
-
1995
- 1995-02-25 GB GBGB9503863.4A patent/GB9503863D0/en active Pending
-
1996
- 1996-02-14 MY MYPI96000567A patent/MY113428A/en unknown
- 1996-02-15 AU AU48780/96A patent/AU695921B2/en not_active Ceased
- 1996-02-15 EP EP96904814A patent/EP0810877B1/en not_active Expired - Lifetime
- 1996-02-15 DE DE69617211T patent/DE69617211T2/en not_active Expired - Lifetime
- 1996-02-15 JP JP52598896A patent/JP3881015B2/en not_active Expired - Fee Related
- 1996-02-15 WO PCT/EP1996/000681 patent/WO1996026741A1/en active IP Right Grant
- 1996-02-15 ES ES96904814T patent/ES2166879T3/en not_active Expired - Lifetime
- 1996-02-15 BR BR9607458A patent/BR9607458A/en not_active IP Right Cessation
- 1996-02-15 PT PT96904814T patent/PT810877E/en unknown
- 1996-02-15 AT AT96904814T patent/ATE209045T1/en active
- 1996-02-15 TR TR97/00849T patent/TR199700849T1/en unknown
- 1996-02-15 CA CA002212552A patent/CA2212552C/en not_active Expired - Fee Related
- 1996-02-15 KR KR1019970705880A patent/KR100365373B1/en not_active IP Right Cessation
- 1996-02-15 CN CN96192146A patent/CN1101225C/en not_active Expired - Fee Related
- 1996-02-15 US US08/894,643 patent/US5972346A/en not_active Expired - Lifetime
- 1996-02-15 PL PL96321966A patent/PL182679B1/en unknown
- 1996-02-15 HU HU9801242A patent/HU224832B1/en not_active IP Right Cessation
- 1996-02-15 EA EA199700126A patent/EA199700126A1/en unknown
- 1996-02-15 SK SK1150-97A patent/SK115097A3/en unknown
- 1996-02-15 CZ CZ19972674A patent/CZ288417B6/en not_active IP Right Cessation
- 1996-02-15 DK DK96904814T patent/DK0810877T3/en active
- 1996-02-15 AP APAP/P/1997/001060A patent/AP766A/en active
- 1996-02-15 NZ NZ302674A patent/NZ302674A/en not_active IP Right Cessation
- 1996-02-22 AR ARP960101469A patent/AR002279A1/en active IP Right Grant
- 1996-02-23 IL IL11724996A patent/IL117249A/en not_active IP Right Cessation
- 1996-02-23 MA MA24171A patent/MA23814A1/en unknown
- 1996-02-23 ZA ZA961460A patent/ZA961460B/en unknown
- 1996-02-26 TW TW085102154A patent/TW467745B/en not_active IP Right Cessation
- 1996-03-02 SA SA96160633A patent/SA96160633B1/en unknown
-
1997
- 1997-08-02 OA OA70066A patent/OA10612A/en unknown
- 1997-08-22 MX MX9706450A patent/MX9706450A/en unknown
- 1997-08-22 NO NO19973873A patent/NO319394B1/en not_active IP Right Cessation
- 1997-08-22 FI FI973457A patent/FI118118B/en not_active IP Right Cessation
- 1997-08-25 BG BG101851A patent/BG101851A/en unknown
-
1998
- 1998-04-28 HK HK98103600A patent/HK1004117A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2212552A1 (en) | Hepatitis b vaccine | |
| AU709406C (en) | Combined vaccines comprising hepatitis B surface antigen and other antigens | |
| USD367384S (en) | Earring pyramid | |
| USD408625S (en) | Container for medical apparatus | |
| CA2132833A1 (en) | Hepatitis vaccines containing 3-o-deacylated monophosphoryl lipid a | |
| USD322002S (en) | Multipurpose wall-mountable caddy | |
| AU6304996A (en) | Vaccines against hepatitis c | |
| AU1018895A (en) | Upright carpet extractor | |
| CA2203943A1 (en) | An apparatus for retaining bone portions in a desired spatial relationship | |
| AU4278696A (en) | Yeast telomerase components and methods using them | |
| AU7375294A (en) | Microemulsion cleaners and their uses | |
| USD396065S (en) | Placard display stand | |
| USD378910S (en) | Vehicle instrument panel | |
| USD311718S (en) | Front wheel balancer | |
| USD316903S (en) | Building for an automotive service station or the like | |
| USD317047S (en) | Building for an automotive service station or the like | |
| USD359530S (en) | Alligator figure | |
| CA2036529A1 (en) | Potato masher | |
| USD375085S (en) | Price verifier | |
| CA2238099A1 (en) | Dental instrument with improved grip | |
| USD360403S (en) | Adapter | |
| USD359531S (en) | Alligator figure | |
| AU6197594A (en) | Copolymer produced in two stages | |
| USD383498S (en) | Decorative drawing for the surface of an article | |
| AU3249497A (en) | Ambiguity resolution in mcps |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140217 |